BMY - Bristol-Myers Squibb Sales Growth YoY (Last Twelve Months)

Graphic logo of bms.com (BMY)

Pressure on operating leverage is increasing due to the loss of patent protection for legacy drugs, yet Bristol-Myers Squibb (BMY) maintains physician confidence through its authority in cardiology and oncology. A broad portfolio of proven medications ensures high margins, as evidenced by the current 12-month trailing revenue dynamics, where the current value stands at 4.20, confirming the revenue resilience of this behemoth.

BMY - BMS Sales Growth YoY (TTM) over the range 02/11/2024 - 11/19/2026

Bristol-Myers Squibb - analytical breakdowns and key metrics (BMY)

- price and consensus price forecast:
Analysis of all company metrics:Bristol-Myers Squibb
Signature product of Bristol-Myers Squibb Co.

Bristol-Myers Squibb (BMY) revenues depend on the performance of blockbuster drugs and the success of M&A deals aimed at mitigating patent risks. By analyzing year-over-year revenue changes over the trailing twelve months (TTM), an investor can observe a smoothed business expansion percentage stripped of market noise, where stable growth confirms the efficacy of new drugs, while sharp spikes may signal an overvaluation of the asset.